HITLAB Validates MedsEngine’s Value in Treating Chronic Diseases
HITLAB, affiliated with Columbia University, published a Summary of Evidence Paper on MedsEngine, following an independent evaluation of the platform’s clinical evidence and usability. The assessment, completed in March 2026, covered all four disease modules and evaluated the platform’s integration into clinical workflows.
NEW YORK–(BUSINESS WIRE)–HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine®. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis usin